Lincoln Pharmaceuticals ltd.

BSE: LINCOLN531633ISIN INE405C01035

Healthcare
Pharmaceuticals
BSE Healthcare

BSE listing

Share price

₹606.40+5.20 (+0.86%)

as of 18 Sep 2026

52W high: ₹770.00
52W low: ₹439.95
Off 52W high: -21.25%
1M return: -0.79%
3M return: -1.07%
6M return: +0.85%
1Y return: +9.53%
20D avg volume: 3,622
50 DMA: ₹605.85
200 DMA: ₹583.60

Key ratios Consolidated

Market cap: ₹1,215 Cr
Current price: ₹606.40
52W high / low: ₹770.00 / ₹439.95
Face value: ₹10.00
P/E: 12.59
P/B: —
EPS (TTM): ₹48.16
Book value / share: —
ROE: —
ROCE: 15.00%
Operating margin: —
Net margin: —
Debt / equity: 0.01
Net debt: ₹-17.11 Cr
Interest cover: 115.48
Dividend yield: 0.30%
Dividend / share (TTM): ₹1.80
Payout: 3.74%
Cash conversion cycle: 85.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	177.28	187.28	166.32	163.36	154.07	168.18	—
	24.26	-4.20	15.15	7.23	15.27	-6.88	—
	153.99	166.38	146.75	141.79	133.95	145.06	—
	58.58	73.73	47.68	57.20	60.97	53.93	—
	20.93	16.45	25.03	21.72	15.83	14.75	—
	33.31	32.46	30.62	30.36	31.76	27.62	—
	0.26	0.27	0.30	0.23	0.21	0.37	—
	3.88	3.68	3.72	3.62	3.48	3.23	—
	31.40	40.89	36.15	30.83	29.12	33.69	—
	47.55	16.70	34.72	28.81	35.39	16.25	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	47.55	16.70	34.72	28.81	35.39	16.25	—
	11.32	5.07	6.12	8.83	7.71	4.67	—
	36.23	11.63	28.60	19.98	27.68	11.57	—
	18.09	5.81	14.28	9.98	13.82	5.78	—
Key metrics
	51.69	20.65	38.74	32.66	39.08	19.85	—
	29.20%	11.00%	23.30%	20.00%	25.40%	11.80%	—
	20.40%	6.20%	17.20%	12.20%	18.00%	6.90%	—
	—	2.20%	—	3.90%	—	2.40%	—
	15.10%	11.40%	—	—	—	—	—
	30.90%	0.50%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	694.24	671.03	623.23	—
	42.44	33.45	22.48	—
	608.91	588.86	536.52	—
	237.19	239.57	213.94	—
	84.13	79.03	68.54	—
	126.75	125.19	112.45	—
	1.06	1.01	1.88	—
	14.90	14.50	12.90	—
	139.27	137.00	117.96	—
	127.78	115.62	109.19	—
	0.00	0.00	0.00	—
	127.78	115.62	109.19	—
	31.34	27.73	26.84	—
	96.44	87.89	82.35	—
	48.16	43.88	41.11	—
Key metrics
	143.74	131.13	123.97	—
	20.70%	19.50%	19.90%	—
	13.89%	13.10%	13.20%	—
	—	15.00%	16.10%	—
	—	7.70%	—	—
	—	6.70%	—	—
	—	80.93	73.99	—
	—	1.21	1.13	—
	—	0.01	0.00	—
	—	-17.11	-13.41	—
	—	85.2	93.8	—
Balance sheet
	—	890.40	797.01	—
	—	583.06	499.94	—
	—	21.53	13.41	—
	—	161.45	166.40	—
	—	80.11	78.68	—
	—	18.65	21.56	—
	—	190.03	181.53	—
	—	84.86	84.95	—
	—	111.04	106.22	—
	—	4.42	0.00	—
	—	4.42	0.00	—
	—	0.00	0.00	—
	—	757.63	671.67	—
Cash flow
	—	106.36	93.02	—
	—	-98.40	-78.95	—
	—	0.16	-6.40	—
	—	25.43	19.03	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	177.28	187.28	166.32	163.36	154.07	168.18	—
	24.26	-4.20	15.15	7.23	15.27	-6.88	—
	153.99	166.38	146.75	141.79	133.95	145.06	—
	58.58	73.73	47.68	57.20	60.97	53.93	—
	20.93	16.45	25.03	21.72	15.83	14.75	—
	33.31	32.46	30.62	30.36	31.76	27.62	—
	0.26	0.27	0.30	0.23	0.21	0.37	—
	3.88	3.68	3.72	3.62	3.48	3.23	—
	31.40	40.89	36.15	30.83	29.12	33.69	—
	47.55	16.70	34.72	28.81	35.39	16.25	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	47.55	16.70	34.72	28.81	35.39	16.25	—
	11.32	5.07	6.12	8.83	7.71	4.67	—
	36.23	11.63	28.60	19.98	27.68	11.57	—
	18.09	5.81	14.28	9.98	13.82	5.78	—
Key metrics
	51.69	20.65	38.74	32.66	39.08	19.85	—
	29.20%	11.00%	23.30%	20.00%	25.40%	11.80%	—
	20.40%	6.20%	17.20%	12.20%	18.00%	6.90%	—
	—	2.20%	—	3.90%	—	2.40%	—
	15.10%	11.40%	—	—	—	—	—
	30.90%	0.50%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	694.24	671.03	623.23	—
	42.44	33.45	22.48	—
	608.91	588.86	536.52	—
	237.19	239.57	213.94	—
	84.13	79.03	68.54	—
	126.75	125.19	112.45	—
	1.06	1.01	1.88	—
	14.90	14.50	12.90	—
	139.27	137.00	117.96	—
	127.78	115.62	109.19	—
	0.00	0.00	0.00	—
	127.78	115.62	109.19	—
	31.34	27.73	26.84	—
	96.44	87.89	82.35	—
	48.16	43.88	41.11	—
Key metrics
	143.74	131.13	123.97	—
	20.70%	19.50%	19.90%	—
	13.89%	13.10%	13.20%	—
	—	15.00%	16.10%	—
	—	7.70%	—	—
	—	6.70%	—	—
	—	80.93	73.99	—
	—	1.21	1.13	—
	—	0.01	0.00	—
	—	-16.67	-12.97	—
	—	84.8	93.3	—
Balance sheet
	—	890.26	796.87	—
	—	582.87	499.75	—
	—	21.09	12.97	—
	—	160.58	165.53	—
	—	80.11	78.68	—
	—	18.55	21.46	—
	—	190.03	181.53	—
	—	84.72	84.81	—
	—	110.90	106.08	—
	—	4.42	0.00	—
	—	4.42	0.00	—
	—	0.00	0.00	—
	—	757.63	671.67	—
Cash flow
	—	106.36	93.02	—
	—	-98.40	-78.95	—
	—	0.16	-6.40	—
	—	25.43	19.03	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 49.77%

Holder	Type	Holding	Previous	Change
Munjal Mahendrabhai Patel	Promoter Group	13.37%	—	—
Ashish Rajanikant Patel	Promoter Group	10.60%	—	—
Rajanikant Gulabdas Patel	Promoter	3.78%	—	—
Mahendrabhai Gulabdas Patel	Promoter	3.37%	—	—
Sunmed Corporation Llp	Promoter Group	2.50%	—	—
Kailashben Mahendrabhai Patel	Promoter Group	2.40%	—	—
Kishor M. Shah	Public	2.39%	—	—
Downtown Travels Llp	Promoter Group	2.37%	—	—
Hasmukhbhai Ishwarbhai Patel	Promoter	1.87%	—	—
Anand Arvinbhai Patel	Promoter Group	1.66%	—	—
Rimo Capital Fund Lp	Public	1.35%	—	—
Dheeraj Kumar Lohia	Public	1.24%	—	—
Shivani Ashish Patel	Promoter Group	1.03%	—	—
Mansi Munjal Patel	Promoter Group	1.00%	—	—
Hansaben Arvindbhai Patel	Promoter Group	0.88%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Newspaper Publication for Notice of 32nd Annual General Meeting.7 Sep 2026 · Company Update / Newspaper Publication
Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address.5 Sep 2026 · Company Update / General
Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the SEBI Listing Regulations"), we are submitting ....5 Sep 2026 · Others / Reg. 34 (1) Annual Report
32nd Annual General Meeting ("AGM") of the Members of the Company will be held on Wednesday, 30th September, 2026 at 11:00 A.M. (IST) through Video Conferencing ("VC")/Other Audio-Visual ....5 Sep 2026 · AGM/EGM / AGM
The intimation of Book Closure and Record date is as enclosed.29 Aug 2026 · Corp. Action / Record Date
Pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015, we would like to inform you that the 32nd Annual General Meeting of the Company is scheduled to be held on Wednesday, September ....29 Aug 2026 · Corp. Action / Book Closure
Newspaper Advertisement regarding the 32nd Annual General Meeting of the Company to be held on Wednesday, September 30, 2026.26 Aug 2026 · Company Update / Newspaper Publication
We enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June, 2026.14 Aug 2026 · Company Update / Newspaper Publication
Un-Audited Financial Results For Quarter Ended on 30 June, 2026.13 Aug 2026 · Result / Financial Results
Un-Audited Financial Results of the Company For the Quarter Ended June 30, 2026.13 Aug 2026 · Board Meeting / Outcome of Board Meeting
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Lincoln Pharmaceuticals ....6 Aug 2026 · Board Meeting / Board Meeting
Pursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation, 2018, we hereby submit the confirmation certificate received from MUFG Intime India Private Limited, ....6 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Trading Window Closure for the Quarter ended June 30, 2026.24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
We enclosed herewith the copies of published newspaper advertisement with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Year ended March 31, 2026.29 May 2026 · Company Update / Newspaper Publication
Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity share of face value Rs. 10/- each for the financial year ended March 31, 2026 subject to approval of the members at the ensuing ....28 May 2026 · Corp. Action / Dividend
Audited Financial Results for the Quarter and Year ended March 31, 2026.28 May 2026 · Result / Financial Results
Outcome of Board Meeting for Audited Financial Results for the Quarter and Year Ended 31st March, 2026.28 May 2026 · Board Meeting / Outcome of Board Meeting
Meeting of the Board of Directors is scheduled to be held on May 28, 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares ....18 May 2026 · Corp. Action / Dividend
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Audited (standalone ....18 May 2026 · Board Meeting / Board Meeting
Annual Secretarial Compliance Report for the financial year ended March 31, 2026.12 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund)Rules, 2016 and amendments thereof.8 May 2026 · Company Update / Newspaper Publication
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''> <tr> <td>Sr. No.</td> <td>Particulars</td> ....5 May 2026 · Others / Format of the Annual Disclosure to be made by an entity identified as a LC : Annexure B2
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....16 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Pursuant to Provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation, 2018, We hereby submit the confirmation Certificate received from MUFG Intime India Private Limited, ....6 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window.25 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Regulation of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 we attach herewith transcript of conference call held on February 18, 2026. A copy of ....23 Feb 2026 · Company Update / Earnings Call Transcript
We wish to inform you that the Company participated in investor conference- Call Conference on February 18, 2026. No Unpublished Price Sensitive Information (UPSI) was shared / discussed ....18 Feb 2026 · Company Update / Analyst / Investor Meet
Intimation of Schedule of earnings conference call to discuss the unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2025.13 Feb 2026 · Company Update / Analyst / Investor Meet
Newspaper Advertisement with respect to unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended on December 31, 2025.13 Feb 2026 · Company Update / Newspaper Publication
Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31.12.2025.12 Feb 2026 · Result / Financial Results
Outcome of the meeting held today12 Feb 2026 · Board Meeting / Outcome of Board Meeting
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve unaudited Financial ....4 Feb 2026 · Board Meeting / Board Meeting
Update on Credit Rating.10 Jan 2026 · Company Update / Credit Rating
Pursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation, 2018, we hereby submit the confirmation certificate received from MUFG Intime India Private Limited, ....6 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window24 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, we enclosed herewith the copies of newspaper intimation with respect to un-audited financial results for the quarter and half ....14 Nov 2025 · Company Update / Newspaper Publication
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.202513 Nov 2025 · Result / Financial Results
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.202513 Nov 2025 · Board Meeting / Outcome of Board Meeting
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve Standalone and Consolidated ....5 Nov 2025 · Board Meeting / Board Meeting
With reference to the above, please find enclosed herewith the Minutes of 31st Annual General Meeting of the Company held at 11:00 A.M on Tuesday, the 30th September, 2025 through Video ....28 Oct 2025 · AGM/EGM / AGM

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.8000	11 Sep 2026	11 Sep 2026	—
Final Dividend - Rs. - 1.8000	12 Sep 2025	12 Sep 2025	—
Final Dividend - Rs. - 1.8000	13 Sep 2024	—	—

Board meetings

13 Aug 2026 Board Meeting - Financial Results